← Product Code [JWY](/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JWY) · K020820 # MICROSCAN MICROSTEP PLUS PANEL NEW ANTIMICROBIAL - CEFUROXIME (K020820) _Dade Behring, Inc. · JWY · May 9, 2002 · Microbiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JWY/K020820 ## Device Facts - **Applicant:** Dade Behring, Inc. - **Product Code:** [JWY](/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JWY.md) - **Decision Date:** May 9, 2002 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.1640 - **Device Class:** Class 2 - **Review Panel:** Microbiology ## Indications for Use To determine bacterial antimicrobial agent susceptibility. The MicroScan® MICroSTREP plus™ Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of aerobic streptococci, including Streptococcus pneumoniae. After inoculation, panels are incubated for 20 - 24 hours at 35℃ +/- 1℃ in a non-CO2 incubator, and read visually according to the Package Insert. This particular submission is for the addition of the antimicrobial Cefuroxime at concentrations of 0.12 to 8 mcg/ml to the test panel. The organisms which may be used for Cefuroxime susceptibility testing in this panel are: Streptococcus pneumoniae ## Device Story MicroScan® MICroSTREP plus™ Panel is a miniaturized broth dilution susceptibility test system. Input: bacterial colonies grown on solid media. Process: panels rehydrated with Mueller-Hinton broth supplemented with 2-5% lysed horse blood and 50 mM HEPES; inoculated with standardized organism suspension; incubated 20-24 hours at 35°C in non-CO2 incubator. Output: visual determination of minimum inhibitory concentration (MIC) by observing lowest antimicrobial concentration inhibiting growth. Used in clinical laboratories by trained personnel. Results assist clinicians in selecting appropriate antimicrobial therapy for patients with streptococcal infections. ## Clinical Evidence Bench testing only. Performance evaluated by comparing the MicroScan® MICroSTREP plus™ Panel to an NCCLS frozen Reference Panel using fresh and stock Efficacy isolates and stock Challenge strains. Results showed >99% Essential Agreement for Cefuroxime. Reproducibility and Quality Control testing met acceptance criteria. ## Technological Characteristics Miniaturized broth dilution panel. Rehydrated with Mueller-Hinton broth, 2-5% lysed horse blood, and 50 mM HEPES. Manual visual reading of growth inhibition. Cefuroxime concentrations: 0.12-8 ug/ml. ## Regulatory Identification An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases. ## Predicate Devices - MicroScan® Streptococcus MIC Panel ([K963641](/device/K963641.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K620820 MAY 0 9 2002 ## 510(k) Summarv Information: | Device Manufacturer: | Dade MicroScan Inc. | |----------------------|---------------------------------------------------------------------------| | Contact name: | Cynthia Van Duker, Regulatory Affairs Manager | | Fax: | 916-374-3144 | | Date prepared: | March 12, 2002 | | Product Name: | Microdilution Minimum Inhibitory Concentration (MIC) Panels | | Trade Name: | MicroScan® MICroSTREP plus™ Panel | | Intended Use: | To determine bacterial susceptibility to Cefuroxime | | Indication for Use | For determining antimicrobic susceptibility with Streptococcus pneumoniae | | Predicate device: | MicroScan® Streptococcus MIC Panel (K963641). | ## 510(k) Summary: The MicroScan® MICroSTREP plus™ Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of aerobic streptococci, including Streptococcus pneumoniae. After inoculation, panels are incubated for 20 - 24 hours at 35°C +/- 1°C in a non-CO2 incubator, and read visually according to the Package Insert. The antimicrobial susceptibility tests are miniaturizations of the broth dilution susceptibility test. Various antimicrobial agents are diluted in water, buffer or minute concentrations of broth to concentrations bridging the range of clinical interest. Panels are rehydrated with 115 ul Mueller-Hinton broth supplemented with 2-5% lysed horse blood (1.HB) and buffered with 50 mM HEPES, after inoculation of the broth with a standardized suspension of the organism in saline. After incubation in a non-CO2 incubator for 20-24 hours, the minimum inhibitory concentration (MIC) for the test organism is manually read by observing the lowest antimicrobial concentration showing inhibition of growth. The proposed MicroScan® MICroSTREP plus™ Panel demonstrated substantially equivalent performance with streptococcal isolates when compared with an NCCLS frozen Reference Panel, as defined in the FDA DRAFT document "Guidance on Review Criteria for Assessment of Antimicrobial Susceptibility Devices", dated March 8, 2000. The Premarket Notification (510|k|) presents data in support of the new MCcoSTREP plus™ with Cefuroxime. The external evaluation was conducted with fresh and stock Efficacy isolates and stock Challenge strains. The external evaluations were designed to confirm the acceptability of the proposed MICroSTREP plus™ Panel by comparing its performance with an NCCLS frozen Reference panel. The MCroSTREP plus™ Panel demonstrated acceptable performance with an overall Essential Agreement of >99% for Cefuroxime when compared with the frozen Reference panel. Reproducibility testing demonstrated acceptable reproducibility and precision with Cefuroxime. Quality Control testing demonstrated acceptable results for Cefuroxime. {1}------------------------------------------------ DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/1/Picture/1 description: The image is a seal for the Department of Health & Human Services - USA. The seal is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is a stylized image of three human profiles facing to the right. The profiles are connected and appear to be part of a single, continuous line. Food and Drug Administration 2098 Gaither Road Rockville MD 20850 MAY 0 9 2002 Ms. Cynthia Van Duker Regulatory Affairs Manager Dade Behring Inc. 1584 Enterprise Boulevard West Sacramento, CA 95691 k020820 Re: Rozoozo Trade/Device Name: MicroScan® MICroSTREP plus™ Panels with Cefuroxime 0.12-8 ug/ml. Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial Susceptibility Test Regulatory Class: Class II Product Code: JWY Dated: March 12, 2002 Received: March 13, 2002 Dear Ms. Van Duker: We have reviewed your Section 510(k) premarket notification of intent to market the device wt nave reviewed your becaller of the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for ass bared in the May 28, 1976, the enactment date of the Medical Device Amendments, or to conmision provision of the J 2005 and with the provisions of the Federal Food, Drug, do noos mat have been require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The r ou may , are s provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it If your de reast additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean r four ove active a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must or any I with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set orth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {2}------------------------------------------------ Page 2 - This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html". Sincerely yours, Steven Butman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ ## Indication for Use Statement 510(k) No .: Device Name: Intended Use Indications for Use: K020820 (To be assigned by FDA) MicroScan® MICroSTREP plus™ Panel To determine bacterial antimicrobial agent susceptibility The MicroScan® MICroSTREP plus™ Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of aerobic streptococci, including Streptococcus pneumoniae. After inoculation, panels are incubated for 20 - 24 hours at 35℃ +/- 1℃ in a non-CO2 incubator, and read visually according to the Package Insert. This particular submission is for the addition of the antimicrobial Cefuroxime at concentrations of 0.12 to 8 mcg/ml to the test panel The organisms which may be used for Cefuroxime susceptibility testing in this panel are: Streptococcus pneumoniae (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) | (Division Sign- | | |-----------------|---------------| | Division of Cli | atory Devices | | 510(k) Number | k0 20826 | |---------------|----------| |---------------|----------| | Prescription Use | | |----------------------|----------------------| | (Per 21 CFR 801.109) | OR | | | Over-The-Counter Use | (Optional Format 1-2-96) 8 --- **Source:** [https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JWY/K020820](https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JWY/K020820) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com